Program
mivelsiran
Also written as “ALN-APP” and “Mivelsiran”.
Its studies are mostly in Cerebral Amyloid Angiopathy · Alzheimer Disease · Down Syndrome, led by Alnylam Pharmaceuticals.
Furthest: phase 2, since Apr 19, 20243 company-led studies, 3 open or runningNext primary completion: Aug 9, 2027 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Alnylam Pharmaceuticals | 33 open or running | phase 2since Apr 19, 2024 | Jan 30, 2022 | Aug 9, 2027phase 2 · NCT06393712 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jan 30, 2022First study: phase 1 study in Alzheimer DiseaseFirst studyNCT05231785 · 60 planned · United States, Canada, Netherlands and more
- Apr 19, 2024Phase 2 study in Cerebral Amyloid AngiopathyNCT06393712 · 210 enrolled · United States, Australia, Canada and more
- Jun 4, 2026Phase 2 study in Down SyndromeNCT07636811 · 58 planned · United States, Spain
Ahead
- Aug 9, 2027Primary completion: phase 2 study in Cerebral Amyloid AngiopathyNCT06393712
- Jan 11, 2029Primary completion: phase 1 study in Alzheimer DiseaseNCT05231785
- May 18, 2030Primary completion: phase 2 study in Down SyndromeNCT07636811
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07636811Down Syndrome · United States, Spain | 2 | Recruiting | May 18, 2030 | 58 |
| NCT06393712Cerebral Amyloid Angiopathy · United States, Australia, Canada and more | 2 | Active, not recruiting | Aug 9, 2027 | 210 |
| NCT05231785Alzheimer Disease · United States, Canada, Netherlands and more | 1 | Recruiting | Jan 11, 2029 | 60 |
How it is read
Names in the registry
- “ALN-APP”, 2 entries
- “Mivelsiran”, 1 entry
Conditions, from the studies’ own filings
- Cerebral Amyloid Angiopathy, 1 study
- Alzheimer Disease, 1 study
- Down Syndrome, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.